

Andrea Balsari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3951733/publications.pdf>

Version: 2024-02-01

175
papers

6,076
citations

76326

40
h-index

91884

69
g-index

177
all docs

177
docs citations

177
times ranked

7915
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer. <i>Cancer Research</i> , 2021, 81, 2195-2206.	0.9	63
2	Aerosol 1,25-dihydroxyvitamin D3 supplementation: A strategy to boost anti-tumor innate immune activity. <i>PLoS ONE</i> , 2021, 16, e0248789.	2.5	4
3	Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain. <i>Cancers</i> , 2021, 13, 4081.	3.7	5
4	Combined targeting of EGFR and HER2 against prostate cancer stem cells. <i>Cancer Biology and Therapy</i> , 2020, 21, 463-475.	3.4	13
5	TLR3 Expression Induces Apoptosis in Human Non-Small-Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1440.	4.1	37
6	The lung microbiota: role in maintaining pulmonary immune homeostasis and its implications in cancer development and therapy. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 2739-2749.	5.4	103
7	Local Administration of Caloric Restriction Mimetics to Promote the Immune Control of Lung Metastases. <i>Journal of Immunology Research</i> , 2019, 2019, 1-8.	2.2	15
8	Inhibition of DNA Repair Mechanisms and Induction of Apoptosis in Triple Negative Breast Cancer Cells Expressing the Human Herpesvirus 6 U94. <i>Cancers</i> , 2019, 11, 1006.	3.7	13
9	Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients. <i>Scientific Reports</i> , 2019, 9, 14288.	3.3	17
10	HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy. <i>Oncolmmunology</i> , 2019, 8, e1512942.	4.6	57
11	Modulation of Pulmonary Microbiota by Antibiotic or Probiotic Aerosol Therapy: A Strategy to Promote Immunosurveillance against Lung Metastases. <i>Cell Reports</i> , 2018, 24, 3528-3538.	6.4	141
12	Activation of NK cell cytotoxicity by aerosolized CpG-ODN/poly(I:C) against lung melanoma metastases is mediated by alveolar macrophages. <i>Cellular Immunology</i> , 2017, 313, 52-58.	3.0	25
13	Exploiting poly(I:C) to induce cancer cell apoptosis. <i>Cancer Biology and Therapy</i> , 2017, 18, 747-756.	3.4	92
14	Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor. <i>Oncolmmunology</i> , 2016, 5, e1234571.	4.6	30
15	Expression and prognostic significance of the autoimmune regulator gene in breast cancer cells. <i>Cell Cycle</i> , 2016, 15, 3220-3229.	2.6	16
16	CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts. <i>Journal of Translational Medicine</i> , 2016, 14, 25.	4.4	17
17	Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. <i>Oncotarget</i> , 2016, 7, 255-265.	1.8	39
18	miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response. <i>Oncotarget</i> , 2016, 7, 786-797.	1.8	70

#	ARTICLE	IF	CITATIONS
19	Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment. <i>Oncolmunology</i> , 2015, 4, e1040214.	4.6	37
20	Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration. <i>Oncotarget</i> , 2015, 6, 28173-28182.	1.8	34
21	Aerosol Delivery in the Treatment of Lung Cancer. <i>Current Cancer Drug Targets</i> , 2015, 15, 604-612.	1.6	18
22	Prognostic role of tumor size in T1 HER2-positive breast cancers treated with adjuvant trastuzumab. <i>Annals of Oncology</i> , 2014, 25, 1073-1074.	1.2	4
23	Maspin influences response to doxorubicin by changing the tumor microenvironment organization. <i>International Journal of Cancer</i> , 2014, 134, 2789-2797.	5.1	13
24	Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis. <i>Molecular Cancer</i> , 2014, 13, 23.	19.2	11
25	PDGFR β and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells. <i>Molecular Oncology</i> , 2014, 8, 968-981.	4.6	37
26	High efficacy of CpG-ODN, Cetuximab and Cisplatin combination for very advanced ovarian xenograft tumors. <i>Journal of Translational Medicine</i> , 2013, 11, 25.	4.4	18
27	Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 101-110.	2.5	25
28	Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases. <i>International Journal of Cancer</i> , 2013, 133, 383-393.	5.1	20
29	EGFR through STAT3 modulates β -N63 expression to sustain tumor-initiating cell proliferation in squamous cell carcinomas. <i>Journal of Cellular Physiology</i> , 2013, 228, 871-878.	4.1	24
30	FOXP3 expression in tumor cells and implications for cancer progression. <i>Journal of Cellular Physiology</i> , 2013, 228, 30-35.	4.1	87
31	Influence of fatty acid-free diet on mammary tumor development and growth rate in HER2/neu transgenic mice. <i>Journal of Cellular Physiology</i> , 2013, 228, 242-249.	4.1	7
32	Neoplastic and Stromal Cells Contribute to an Extracellular Matrix Gene Expression Profile Defining a Breast Cancer Subtype Likely to Progress. <i>PLoS ONE</i> , 2013, 8, e56761.	2.5	41
33	Increased Sensitivity to Chemotherapy Induced by CpG-ODN Treatment Is Mediated by microRNA Modulation. <i>PLoS ONE</i> , 2013, 8, e58849.	2.5	21
34	Modulation of DNA repair genes induced by TLR9 agonists. <i>Oncolmunology</i> , 2012, 1, 258-259.	4.6	4
35	PET Prediction of Response to Trastuzumab in ErbB2-Positive Human Xenograft Model. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1654-1655.	5.0	1
36	Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34+ cells in a xenograft model. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 457-467.	2.5	5

#	ARTICLE	IF	CITATIONS
37	Activity and resistance of trastuzumab according to different clinical settings. <i>Cancer Treatment Reviews</i> , 2012, 38, 212-217.	7.7	31
38	Induction of Paneth cell degranulation by orally administered Toll-like receptor ligands. <i>Journal of Cellular Physiology</i> , 2012, 227, 1107-1113.	4.1	56
39	Stimulation of TLRs by LMW- α -HA induces self-defense mechanisms in vaginal epithelium. <i>Immunology and Cell Biology</i> , 2011, 89, 630-639.	2.3	34
40	Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 147-154.	2.5	23
41	The HER2 World: Better Treatment Selection for Better Outcome. <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 82-85.	2.1	7
42	TLR9 Agonists Oppositely Modulate DNA Repair Genes in Tumor versus Immune Cells and Enhance Chemotherapy Effects. <i>Cancer Research</i> , 2011, 71, 6382-6390.	0.9	37
43	Ascites Regression and Survival Increase in Mice Bearing Advanced-stage Human Ovarian Carcinomas and Repeatedly Treated Intraperitoneally With CpG-ODN. <i>Journal of Immunotherapy</i> , 2010, 33, 8-15.	2.4	26
44	Dansyl α -D-Glucoside as a Novel Agent Against Endotoxic Shock. <i>ChemMedChem</i> , 2010, 5, 1677-1680.	3.2	9
45	Influence of Lignans Depletion on Murine Mammary Gland Morphology. <i>Nutrition and Cancer</i> , 2010, 62, 237-242.	2.0	3
46	HER2 as a target for breast cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 711-724.	3.1	78
47	Expression Profile of Tyrosine Phosphatases in HER2 Breast Cancer Cells and Tumors. <i>Analytical Cellular Pathology</i> , 2010, 32, 361-372.	1.4	5
48	Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors. <i>Cellular Oncology</i> , 2010, 32, 361-72.	1.9	48
49	Toll-like Receptors 3, 4, and 7 Are Expressed in the Enteric Nervous System and Dorsal Root Ganglia. <i>Journal of Histochemistry and Cytochemistry</i> , 2009, 57, 1013-1023.	2.5	237
50	FOXP3 Expression and Overall Survival in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 1746-1752.	1.6	271
51	Intestinal Glucose Uptake Protects Liver from Lipopolysaccharide and d-Galactosamine, Acetaminophen, and Alpha-Amanitin in Mice. <i>American Journal of Pathology</i> , 2009, 175, 1066-1076.	3.8	11
52	Matured human monocyte-derived dendritic cells (MoDCs) induce expansion of CD4+CD25+FOXP3+ T cells lacking regulatory properties. <i>Immunology Letters</i> , 2008, 117, 106-113.	2.5	5
53	Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft. <i>Cancer Biology and Therapy</i> , 2008, 7, 596-601.	3.4	9
54	Low Molecular Weight Hyaluronic Acid Increases the Self-Defense of Skin Epithelium by Induction of β -Defensin 2 via TLR2 and TLR4. <i>Journal of Immunology</i> , 2008, 181, 2103-2110.	0.8	155

#	ARTICLE	IF	CITATIONS
55	Sodium-Dependent Glucose Transporter-1 as a Novel Immunological Player in the Intestinal Mucosa. <i>Journal of Immunology</i> , 2008, 181, 3126-3136.	0.8	33
56	Sodium-dependent glucose transporter-1 as a novel immunological player in the intestinal mucosa.. <i>Journal of Immunology</i> , 2008, 181, 7428.1-7428.	0.8	1
57	Critical Role of TLR9 in Acute Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2008, 181, 6132-6139.	0.8	70
58	Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. <i>Annals of Oncology</i> , 2008, 19, 1706-1712.	1.2	30
59	Induction of pro-inflammatory programs in enteroendocrine cells by the Toll-like receptor agonists flagellin and bacterial LPS. <i>International Immunology</i> , 2008, 20, 961-970.	4.0	47
60	Cross-talk among Toll-like receptors and their ligands. <i>International Immunology</i> , 2008, 20, 709-718.	4.0	28
61	Correction: CCN3 Increases Integrin Expression and Adhesion. <i>Cancer Research</i> , 2008, 68, 2051-2051.	0.9	1
62	Eradication of Ovarian Tumor Xenografts by Locoregional Administration of Targeted Immunotherapy. <i>Clinical Cancer Research</i> , 2008, 14, 5512-5518.	7.0	23
63	CCN3/Nephroblastoma Overexpressed Matricellular Protein Regulates Integrin Expression, Adhesion, and Dissemination in Melanoma. <i>Cancer Research</i> , 2008, 68, 715-723.	0.9	64
64	Two Distinct Local Relapse Subtypes in Invasive Breast Cancer: Effect on their Prognostic Impact. <i>Clinical Cancer Research</i> , 2008, 14, 25-31.	7.0	20
65	Antitumor Efficacy of Trastuzumab in Nude Mice Orthotopically Xenografted With Human Pancreatic Tumor Cells Expressing Low Levels of HER-2/neu. <i>Journal of Immunotherapy</i> , 2008, 31, 537-544.	2.4	16
66	Activation of Enteroendocrine Cells via TLRs Induces Hormone, Chemokine, and Defensin Secretion. <i>Journal of Immunology</i> , 2007, 178, 4296-4303.	0.8	117
67	Cross-talk between Toll-like receptors 5 and 9 on activation of human immune responses. <i>Journal of Leukocyte Biology</i> , 2007, 82, 509-518.	3.3	32
68	Toll-like receptor agonists regulate β -defensin 2 release in hair follicle. <i>British Journal of Dermatology</i> , 2007, 156, 1172-1177.	1.5	17
69	Influence of Antibiotic Treatment on Breast Carcinoma Development in Proto-neu Transgenic Mice. <i>Cancer Research</i> , 2006, 66, 6219-6224.	0.9	43
70	Role of exon-16-deleted HER2 in breast carcinomas. <i>Endocrine-Related Cancer</i> , 2006, 13, 221-232.	3.1	112
71	Linking survival of HER2-positive breast carcinoma patients with surgical invasiveness. <i>European Journal of Cancer</i> , 2006, 42, 1057-1061.	2.8	8
72	Doxorubicin-Induced Alopecia Is Associated with Sebaceous Gland Degeneration. <i>Journal of Investigative Dermatology</i> , 2006, 126, 711-720.	0.7	35

#	ARTICLE	IF	CITATIONS
73	Activation of smooth muscle and myenteric plexus cells of jejunum via toll-like receptor 4. <i>Journal of Cellular Physiology</i> , 2006, 208, 47-54.	4.1	62
74	Antitumor Activity of the TLR-5 Ligand Flagellin in Mouse Models of Cancer. <i>Journal of Immunology</i> , 2006, 176, 6624-6630.	0.8	148
75	Caveolin-1 is expressed on multipotent cells of hair follicles and might be involved in their resistance to chemotherapy. <i>British Journal of Dermatology</i> , 2005, 153, 506-513.	1.5	22
76	CpG-Oligodeoxynucleotides induce mobilization of hematopoietic progenitor cells into peripheral blood in association with mouse KC (IL-8) production. <i>Journal of Cellular Physiology</i> , 2005, 204, 889-895.	4.1	26
77	The 67 kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1. <i>Endocrine-Related Cancer</i> , 2005, 12, 393-406.	3.1	69
78	Therapeutic Synergism of Gemcitabine and CpG-Oligodeoxynucleotides in an Orthotopic Human Pancreatic Carcinoma Xenograft. <i>Cancer Research</i> , 2005, 65, 6388-6393.	0.9	68
79	Apoptosis Induction by Trastuzumab: Possible Role of the Core Biopsy Intervention. <i>Journal of Clinical Oncology</i> , 2005, 23, 7238-7240.	1.6	8
80	Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts. <i>European Journal of Cancer</i> , 2005, 41, 1213-1222.	2.8	23
81	Antibody Response after Vaccination with Antigen-Pulsed Dendritic Cells. <i>International Journal of Biological Markers</i> , 2004, 19, 213-220.	1.8	1
82	Epithelium-mesenchyme compartment interaction and oncosis on chemotherapy-induced hair damage. <i>Laboratory Investigation</i> , 2004, 84, 1404-1417.	3.7	10
83	CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2-specific T lymphocytes but do not lead to a protective tumor-specific memory response. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 697-704.	4.2	6
84	Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts. <i>European Journal of Cancer</i> , 2004, 40, 1275-1281.	2.8	59
85	Degranulation of Paneth Cells via Toll-Like Receptor 9. <i>American Journal of Pathology</i> , 2004, 165, 373-381.	3.8	142
86	Role of proliferation in HER2 status predicted response to doxorubicin. <i>International Journal of Cancer</i> , 2003, 105, 568-573.	5.1	49
87	Thymic function and immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia patients. <i>International Journal of Cancer</i> , 2003, 107, 958-961.	5.1	8
88	Role of hormonal risk factors in HER2-positive breast carcinomas. <i>British Journal of Cancer</i> , 2003, 88, 1032-1034.	6.4	19
89	Role of HER2 in wound-induced breast carcinoma proliferation. <i>Lancet, The</i> , 2003, 362, 527-533.	13.7	152
90	HER2 and proliferation of wound-induced breast carcinoma. <i>Lancet, The</i> , 2003, 362, 1503.	13.7	4

#	ARTICLE	IF	CITATIONS
91	Innate immunity in breast carcinoma.. Endocrine-Related Cancer, 2003, 10, 301-308.	3.1	8
92	HER2 Overexpression and Doxorubicin in Adjuvant Chemotherapy for Resectable Breast Cancer. Journal of Clinical Oncology, 2003, 21, 458-462.	1.6	99
93	Re: Italian Randomized Trial Among Women With Hysterectomy: Tamoxifen and Hormone-Dependent Breast Cancer in High-Risk Women. Journal of the National Cancer Institute, 2003, 95, 917-918.	6.3	1
94	Prediction of response to therapy by biomolecular markers: from the research laboratory to the clinic. Annals of Oncology, 2003, 14, 178-179.	1.2	1
95	Absence of the CD1 Molecule Up-Regulates Antitumor Activity Induced by CpG Oligodeoxynucleotides in Mice. Journal of Immunology, 2002, 169, 151-158.	0.8	34
96	Prevention of spontaneous mammary adenocarcinoma in HER2/neu transgenic mice by foreign DNA. FASEB Journal, 2002, 16, 1749-1754.	0.5	30
97	Humoral immune response for early diagnosis of breast carcinoma. Annals of Oncology, 2002, 13, 483.	1.2	5
98	Most immunoglobulin heavy chain switch mu rearrangements in B-cell chronic lymphocytic leukemia are internal deletions. FEBS Letters, 2002, 518, 119-123.	2.8	10
99	Molecular Phenotype Distinguishes Two Subsets of Gastric Low-Grade Mucosa-Associated Lymphoid Tissue Lymphomas. Laboratory Investigation, 2002, 82, 535-542.	3.7	8
100	HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clinical Cancer Research, 2002, 8, 520-5.	7.0	58
101	Topical administration of a doxorubicin-specific monoclonal antibody prevents drug-induced mouth apoptosis in mice. British Journal of Cancer, 2001, 85, 1964-1967.	6.4	5
102	CD11b Expression Identifies CD8+CD28+ T Lymphocytes with Phenotype and Function of Both Naive/Memory and Effector Cells. Journal of Immunology, 2001, 166, 900-907.	0.8	42
103	HER2 as a Prognostic Factor in Breast Cancer. Oncology, 2001, 61, 67-72.	1.9	216
104	Expansion of Rare CD8+CD28 ^{hi} CD11b ^{hi} T Cells With Impaired Effector Functions in HIV-1-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 465-474.	2.1	11
105	Identification of the human switch alpha 2 region from a low-grade malt lymphoma. Mammalian Genome, 2000, 11, 1145-1146.	2.2	0
106	Expansion of Rare CD8+CD28 ^{hi} CD11b ^{hi} T Cells With Impaired Effector Functions in HIV-1-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 465-474.	2.1	14
107	Breast carcinoma in young patients. Lancet, The, 2000, 356, 1113.	13.7	7
108	Detection of aberrant isotype switch recombination in low-grade and high-grade gastric MALT lymphomas. Blood, 2000, 95, 1032-1038.	1.4	25

#	ARTICLE	IF	CITATIONS
109	Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model. <i>Cancer Research</i> , 2000, 60, 273-5.	0.9	41
110	Cooperative effects of <i>Mycobacterium tuberculosis</i> Ag38 gene transduction and interleukin 12 in vaccination against spontaneous tumor development in proto-neu transgenic mice. <i>Cancer Research</i> , 2000, 60, 3777-81.	0.9	7
111	High level antibody response to retrovirus-associated but not to melanocyte lineage-specific antigens in mice protected against B16 melanoma. , 1999, 83, 107-112.		4
112	Fluctuation of HER2 Expression in Breast Carcinomas during the Menstrual Cycle. <i>American Journal of Pathology</i> , 1999, 155, 1543-1547.	3.8	24
113	INHIBITION OF FIBRONECTIN-ACTIVATED MIGRATION OF MICROVASCULAR ENDOTHELIAL CELLS BY INTERLEUKIN-1 β , TUMOUR NECROSIS FACTOR α AND INTERFERON γ . <i>Cytokine</i> , 1999, 11, 134-139.	3.2	8
114	Generation of CD28 α^+ cells from long-term-stimulated CD8+CD28+ T cells: a possible mechanism accounting for the increased number of CD8+CD28 α^+ T cells in HIV-1-infected patients. <i>Journal of Leukocyte Biology</i> , 1999, 65, 641-648.	3.3	23
115	Correlation between tumor vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma. <i>Laboratory Investigation</i> , 1999, 79, 897-902.	3.7	11
116	Anti-tumor immunity induced by murine melanoma cells transduced with the <i>Mycobacterium tuberculosis</i> gene encoding the 38-kDa antigen. <i>Gene Therapy</i> , 1998, 5, 247-252.	4.5	7
117	Segregation of type 1 cytokine production in human peripheral blood lymphocytes: phenotypic differences between IFN- γ and IL-2-producing cells in the CD8+ T cell subset. <i>European Journal of Immunology</i> , 1998, 28, 3630-3638.	2.9	19
118	Lack of Polarized Type 1 or Type 2 Cytokine Profile in Asymptomatic HIV-1-Infected Patients During a Two-Year Bimonthly Follow-Up. <i>Scandinavian Journal of Immunology</i> , 1998, 47, 146-151.	2.7	6
119	Proliferation of breast carcinoma during menstrual phases. <i>Lancet, The</i> , 1998, 352, 148-149.	13.7	16
120	Contribution of CD4+, CD8+CD28+, and CD8+CD28- T cells to CD3+ lymphocyte homeostasis during the natural course of HIV-1 infection.. <i>Journal of Clinical Investigation</i> , 1998, 101, 137-144.	8.2	52
121	Intratribial injection of an anti-doxorubicin monoclonal antibody prevents drug-induced myelotoxicity in mice. <i>British Journal of Cancer</i> , 1997, 75, 656-659.	6.4	7
122	Natural antibodies to IL-2. <i>Biotherapy (Dordrecht, Netherlands)</i> , 1997, 10, 25-28.	0.7	17
123	T Cells From Individuals in Advanced Stages of HIV-1 Infection Do Not Proliferate but Express Activation Antigens in Response to HIV-1-Specific Antigens. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 15, 61-69.	0.3	12
124	Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. <i>Clinical Cancer Research</i> , 1997, 3, 817-9.	7.0	97
125	Characterization of T Cell Subsets Involved in the Production of IFN- γ in Asymptomatic HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 135-141.	1.1	24
126	Nerve growth factor controls proliferation and progression of human prolactinoma cell lines through an autocrine mechanism. <i>Molecular Endocrinology</i> , 1996, 10, 272-285.	3.7	40

#	ARTICLE	IF	CITATIONS
127	Tumor-necrosis-factor-induced fibroblast growth factor-1 acts as a survival factor in a transformed endothelial cell line. <i>American Journal of Pathology</i> , 1996, 149, 945-52.	3.8	7
128	Oral administration of anti-doxorubicin monoclonal antibody prevents chemotherapy-induced gastrointestinal toxicity in mice. <i>Cancer Research</i> , 1996, 56, 2082-5.	0.9	48
129	Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas. <i>British Journal of Cancer</i> , 1995, 72, 1397-1399.	6.4	22
130	A Monoclonal Antibody to the NH2-Terminal Region of Human Interferon- β Inhibits Its Antiproliferative Activity Without Affecting Its Internalization. <i>Journal of Interferon and Cytokine Research</i> , 1995, 15, 197-204.	1.2	5
131	A monoclonal antibody extends the half-life of an anti-HIV oligodeoxynucleotide and targets it to CD4+ cells. <i>Nucleic Acids Research</i> , 1995, 23, 4603-4607.	14.5	4
132	The Differential Response to Interferon β by Normal and Transformed Endothelial Cells. <i>Biochemical and Biophysical Research Communications</i> , 1995, 214, 582-588.	2.1	15
133	Nerve growth factor directs differentiation of the bipotential cell line GH-3 into the mammothroph phenotype. <i>Endocrinology</i> , 1994, 135, 290-298.	2.8	44
134	Modulation of drug-induced cytotoxicity by a bispecific monoclonal antibody that recognizes the epidermal growth factor receptor and doxorubicin. <i>Cancer Immunology, Immunotherapy</i> , 1994, 38, 171-177.	4.2	6
135	Effect of a bifunctional monoclonal antibody directed against a tumor marker and doxorubicin on the growth of epidermoid vulvar carcinoma grafted in athymic mice. <i>Cell Biophysics</i> , 1994, 24-25, 119-126.	0.4	1
136	Relevance of Antibody Valency in EGF Receptor Modulation. <i>Scandinavian Journal of Immunology</i> , 1994, 39, 453-458.	2.7	6
137	Expression of CD28 on CD8+ and CD4+ Lymphocytes During HIV Infection. <i>Scandinavian Journal of Immunology</i> , 1994, 40, 485-490.	2.7	54
138	Nerve growth factor directs differentiation of the bipotential cell line GH-3 into the mammothroph phenotype. <i>Endocrinology</i> , 1994, 135, 290-298.	2.8	20
139	Modulation of drug-induced cytotoxicity by a bispecific monoclonal antibody that recognizes the epidermal growth factor receptor and doxorubicin. <i>Cancer Immunology, Immunotherapy</i> , 1994, 38, 171-177.	4.2	7
140	Expression of activation markers on peripheral-blood lymphocytes following oral administration of bacillus subtilis spores. <i>International Journal of Immunopharmacology</i> , 1993, 15, 87-92.	1.1	18
141	The Detection and Biological Activity of Human Antibodies to IL-2 in Normal Donors. <i>Scandinavian Journal of Immunology</i> , 1993, 38, 472-476.	2.7	35
142	Purification of interleukin-2 antibodies from healthy individuals. <i>Immunology Letters</i> , 1993, 36, 261-266.	2.5	18
143	Nerve growth factor suppresses the transforming phenotype of human prolactinomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 7961-7965.	7.1	80
144	Natural human antibodies to gamma interferon interfere with the immunomodulating activity of the lymphokine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 4447-4451.	7.1	36

#	ARTICLE	IF	CITATIONS
145	Inhibition of the Biological Activity of Human Interferon- $\hat{3}$ by Antipeptide Antibodies. Journal of Interferon Research, 1992, 12, 49-54.	1.2	11
146	Increase in the therapeutic effect of doxorubicin induced by monoclonal antibodies raised against this drug. Pharmacological Research, 1992, 26, 141-143.	7.1	0
147	An anti-doxorubicin monoclonal antibody modulates kinetic and dynamic characteristics of the drug. International Journal of Cancer, 1992, 50, 617-620.	5.1	7
148	Antigen-specific immunodepression induced by doxorubicin-BSA conjugate in mice. International Journal of Immunopharmacology, 1991, 13, 155-158.	1.1	1
149	Anti-drug monoclonal antibodies antagonize toxic effect more than anti-tumor activity of doxorubicin. International Journal of Cancer, 1991, 47, 889-892.	5.1	10
150	Purification of natural human IFN- $\hat{3}$ antibodies. Immunology Letters, 1991, 30, 53-58.	2.5	9
151	Protection of mice against tumor growth by immunization with an oncogene-encoded growth factor.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 4222-4225.	7.1	14
152	A new monoclonal antibody recognizing anthracyclenic molecule. Anticancer Research, 1990, 10, 129-32.	1.1	9
153	Skin and Perivascular Toxicity Induced Experimentally by Doxorubicin. Journal of Chemotherapy, 1989, 1, 324-329.	1.5	13
154	Monoclonal antibodies against doxorubicin. International Journal of Cancer, 1988, 42, 798-802.	5.1	15
155	Antibacterial activity and pharmacokinetics in mice of two new derivatives of norfloxacin. Chemioterapia: International Journal of the Mediterranean Society of Chemotherapy, 1987, 6, 176-8.	0.0	0
156	Control of human melanoma growth in nude mice by autologous allo-activated peripheral blood lymphocytes. International Journal of Cancer, 1986, 38, 923-927.	5.1	2
157	Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. Cancer Immunology, Immunotherapy, 1986, 21, 148-55.	4.2	27
158	Immune response to autologous human melanoma: implication of class I and II MHC products. Biochimica Et Biophysica Acta: Reviews on Cancer, 1986, 865, 235-251.	7.4	6
159	Adoptive immunotherapy of cancer with immune and activated lymphocytes: Experimental and clinical studies. Research in Clinic and Laboratory, 1986, 16, 1-20.	0.3	7
160	Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells. Cancer and Metastasis Reviews, 1985, 4, 7-26.	5.9	22
161	Allostimulation of patients' lymphocytes generates both T and NK-like cells cytotoxic for autologous melanoma. British Journal of Cancer, 1985, 52, 73-80.	6.4	21
162	Inhibition of Human Melanoma Growth in Nude Mice by Autologous, Alloactivated Peripheral Blood Lymphocytes. Tumori, 1984, 70, 35-39.	1.1	11

#	ARTICLE	IF	CITATIONS
163	Primary but not metastatic human melanomas expressing dr antigens stimulate autologous lymphocytes. <i>International Journal of Cancer</i> , 1984, 33, 591-597.	5.1	91
164	The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA-DR antigens on the tumor cells. <i>International Journal of Cancer</i> , 1984, 34, 797-806.	5.1	63
165	Human Renal Antigen Defined by a Murine Monoclonal Antibody ² . <i>Journal of the National Cancer Institute</i> , 1984, 73, 363-369.	6.3	12
166	Inhibition of human melanoma growth in nude mice by autologous, alloactivated peripheral blood lymphocytes. <i>Tumori</i> , 1984, 70, 35-9.	1.1	5
167	Chemotactic activity for mononuclear phagocytes of culture supernatants from murine and human tumor cells: Evidence for a role in the regulation of the macrophage content of neoplastic tissues. <i>International Journal of Cancer</i> , 1983, 31, 55-63.	5.1	55
168	Regulation of the macrophage content of neoplasms by chemoattractants. <i>Science</i> , 1983, 220, 210-212.	12.6	336
169	Lysis of autologous human melanoma cells by in vitro allosensitized peripheral blood lymphocytes. <i>Cancer Immunology, Immunotherapy</i> , 1982, 14, 99-104.	4.2	31
170	Dermatophytes in clinically healthy laboratory animals. <i>Laboratory Animals</i> , 1981, 15, 75-78.	1.0	26
171	Microplate enzyme-linked immunosorbent assay for bovine leukemia virus antibody. <i>Journal of Clinical Microbiology</i> , 1981, 13, 46-48.	3.9	10
172	<i>Aspergillus fumigatus</i> and specific precipitins in dogs with turbinate changes. <i>Veterinary Record</i> , 1981, 108, 143-145.	0.3	10
173	ELISA for toxoplasma antibody detection: a comparison with other serodiagnostic tests.. <i>Journal of Clinical Pathology</i> , 1980, 33, 640-643.	2.0	37
174	Serological comparison of Bovid herpesvirus 2 and Herpes simplex virus by reciprocal neutralization kinetic studies. <i>Comparative Immunology, Microbiology and Infectious Diseases</i> , 1980, 3, 509-515.	1.6	4
175	Virucidal activity of organic acids. <i>Food Chemistry</i> , 1979, 4, 251-258.	8.2	13